[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512554":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":43,"responsibleParty":60,"collaborators":62,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":25,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Ochsner Health System","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Therasphere Transarterial Radioembolization","ACTIVE_COMPARATOR","Two-phase treatment including mapping angiogram with personalized dosimetry followed by complete treatment of the tumor angiosome with 90-Yittrium glass microsphere infusion.",[13],"Device: Therasphere 90Y",{"label":15,"type":10,"description":16,"interventionNames":17},"Microwave Ablation","Ablation performed with a high powered, gas cooled multi-antenna system targeting an ablative margin \\> 5mm.",[18],"Device: Microwave Ablation",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Therasphere 90Y","Transarterial Radioembolization",[9],null,{"type":21,"name":15,"description":15,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":31,"role":32},"Ari Cohen, MD","Ochsner Health","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Ken Bode","CONTACT","5048421936","ken.bode@ochsner.org",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Amy Riehm","5047039065","amyriehm@ochsner.org",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Ochsner Main Campus","RECRUITING","New Orleans","Louisiana","70121","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-90.07507,29.95465,{"lat":56,"lon":55},[59],{"name":35,"role":36,"phone":25,"phoneExt":25,"email":38},{"type":61,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[63],{"name":64,"class":65},"Boston Scientific Corporation","INDUSTRY","100512554","90y-transarterial-radioembolization-versus-microwave-ablation-in-small-hepatocellular-carcinoma-with-hypoalbuminemia-100512554",false,"NCT05953961","90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia","Randomized Study of Therapshere 90-Yittrium Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia","REALM","Inclusion Criteria:\n\n* HCC diagnosis according to the Liver Imaging - Reporting Data System (LI-RADS) Criteria as defined in the American Association for the Study of Liver Diseases 2018 HCC practice guidelines\n* Eastern Cooperative Oncology Group score 0 - 1\n* Child-Pugh A - B\n* Bilirubin \\\u003C 2.5 mg\u002FdL\n* Creatinine \\\u003C 2.0 mg\u002FdL\n* No prior liver-directed therapy or systemic therapy for HCC\n* Solitary, unresectable HCC ≤ 3cm\n* Albumin level \\\u003C 3.4 g\u002FdL at HCC diagnosis\n* Tumor anatomical location and angiosome amendable to MWA and 90Y\n\nExclusion Criteria:\n\n* Pregnant women\n* Concurrent malignancy","ALL","18 Years",{"count":77,"type":78},50,"ESTIMATED","INTERVENTIONAL",[81],"NA","This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA). The study will determine whether treatment with 90Y lowers the risk of disease progression within the first year after diagnosis. Participants will be randomized to receive either first cycle 90Y or MWA and then proceed with standard of care.",[84],"Carcinoma, Hepatocellular",[86,87],"Yttrium-90","Hypoalbuminemia","2025-07-30",{"date":90,"type":91},"2025-08-03","ACTUAL",{"date":93,"type":91},"2023-08-08",{"date":95,"type":78},"2027-01",{"name":5,"class":6},1]